Association between FGF20 rs12720208 gene polymorphism and Parkinson’s disease: a meta-analysis

Abstract

Previous studies have claimed the association of rs12720208 polymorphism in the fibroblast growth factor 20 (FGF20) gene with the increased risk of Parkinson's disease (PD), but results from the published data were controversial. The aim of our present meta-analysis was to estimate the overall association between FGF20 rs12720208 polymorphism and the risk of PD. Case-control studies with sufficient data evaluating the association between rs12720208 C/T polymorphism and PD susceptibility were systematically identified in PubMed, OVID, SinoMed, Chinese National Knowledge Infrastructure (CNKI) up to July 10, 2015. A total of 3402 PD patients and 3739 controls from seven case-control studies were collected for this meta-analysis. The pooled odds ratio (OR) with its 95% confidence interval (CI) was calculated to assess the genetic association between FGF20 rs12720208 polymorphism and the risk of PD. In this study, no enough proof was found to prove the association in any genetic models with random-effects model (CT+TT vs. CC: OR=1.147, 95% CI: 0.883-1.489, P=0.304; TT vs. CC+CT: OR=1.754, 95% CI: 0.878-3.505, P=0.112; T vs. C: OR=1.169, 95% CI=0.919-1.487, P=0.204; TT+CC vs. CT: OR=0.906, 95% CI=0.694-1.182, P=0.466). Our results suggest that there is no sufficient evidence to support the association between rs12720208 polymorphism and PD risk. Studies with larger sample size across diverse populations and subgroup analyses are necessary in the future.